Sponsor content

Expanding the NIH’s translational record in infectious, immunologic, and allergic diseases

The National Institute of Allergy and Infectious Diseases’ (NIAID) Technology Transfer and Intellectual Property Office (TTIPO) has been instrumental in advancing innovation, continuously building on the institute’s record of scientific excellence with its partners. To download the full article, please sign in.

Upvote 1 Comment
Page of
Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.